MiMedx Group, Inc. (MDXG) Stock Price & Analysis
MiMedx Group, Inc. (MDXG) closed at USD 4.68 on Thursday, October 15, 2026, down 0.43% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.7; the Oct 15, 2026 session ranged USD 4.66–4.88 on volume of 1,331,062 shares. Market capitalization is $682.97M, with a 52-week range of USD 3.03–7.97 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MDXG.md
Key facts (MDXG)
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 7.4 (range 6–8).
- Total return with dividends: 1Y -29.4% vs S&P 500 +18.1%; 5Y -30.8% vs S&P 500 +85.1%.
- Next earnings: 2026-10-28, EPS estimate USD 0, revenue estimate $68.7M.
Analysts (MDXG)
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 7.4 (low 6, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-27 | Craig-Hallum | Target raised | Buy | $6 → $8 |
| 2026-08-17 | Cantor Fitzgerald | Reiterated | Overweight | $8 |
Total return (dividends reinvested) (MDXG)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -29.4% | -30.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -29.5% | -7.1% |
| Volatility (annualized) | 39.9% | 48.4% |
| Max drawdown | -61.2% (Nov 2025→Apr 2026) | -67.2% (Nov 2021→Sep 2022) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 4.68 |
|---|---|
| Change | ▼ 0.43% (down) |
| Previous Close | USD 4.7 |
| Open | USD 4.76 |
| Day Range | USD 4.66 – 4.88 |
| 52-Week Range | USD 3.03 – 7.97 |
| Volume | 1,331,062 shares |
| Market Cap | $682.97M |
| Exchange | NCM |
Technical Analysis (MDXG)
Nexqual's technical model rates MDXG "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.7 (neutral) |
| vs SMA50 | Above (USD 4.55) |
| MACD | 0.03 (positive) |
Analyst Ratings (MDXG)
Wall Street analysts rate MDXG "Buy" based on 5 analysts, with a mean price target of USD 7.4 (range USD 6–8), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 7.4 |
| High Target | USD 8 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (MDXG)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 0 |
| Revenue Estimate | $68.72M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.05 vs est -0.03 ▼ miss |
| 2026-03-31 | USD -0.05 vs est -0.04 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.11 ▲ beat |
| 2025-09-30 | USD 0.15 vs est 0.08 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (MDXG)
| Total Revenue | $355.17M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -34.70% |
| Gross Margin | +78.85% |
| Operating Margin | -28.69% |
| Profit Margin | +1.76% |
| ROE | +2.88% |
| Debt / Equity | 0.08 |
| Current Ratio | 5.33 |
| Total Cash | $135.84M |
| Total Debt | $17.21M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (MDXG)
Nexqual rates MiMedx Group, Inc.'s overall financial health "Solid" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 79%, operating -29% |
| Balance Sheet | Strong — $136M cash vs $17M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $46M (TTM) |
| Efficiency | Weak — ROE 3%, ROA 1.9% |
Ownership (MDXG)
| Insider Ownership | +2.14% |
|---|---|
| Institutional Ownership | +77.95% |
| Shares Outstanding | 145.93M |
| Float | 114.79M |
| Short % of Float | +8.12% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (MDXG)
MiMedx Group, Inc. is led by Joseph H. Capper (age 61), CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Director | Joseph H. Capper (age 61) |
|---|---|
| Chief Financial Officer | Douglas C. Rice (age 59) |
| SVP of R & D & Medical Affairs and Chief Scientific Officer | John Harper |
| Vice President of Investor Relations & Corporate Strategic Communications | Hilary Dixon |
Major Backers & Investors (MDXG)
Notable institutional backers of MiMedx Group, Inc. include Essex Woodlands Management Inc., Trigran Investments Inc, Nantahala Capital Management, LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Essex Woodlands Management Inc. | 25.56% |
| Trigran Investments Inc | 6.5% |
| Nantahala Capital Management, LLC | 4.32% |
| Paradigm Capital Management | 3.69% |
| Goldman Sachs | 2.42% |
| AQR Capital Management, LLC | 2.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.37% |
| Vanguard Group | 9.83% |
| State Street | 6.69% |
| Geode Capital | 2.85% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt